Besivance News and Research

RSS
InSite and Senju collaborate to develop and market azithromycin ophthalmic solution using DuraSite

InSite and Senju collaborate to develop and market azithromycin ophthalmic solution using DuraSite

InSite Vision starts patient enrollment in confirmatory Phase 3 clinical trial of BromSite

InSite Vision starts patient enrollment in confirmatory Phase 3 clinical trial of BromSite

InSite Vision completes enrollment in BromSite Phase 3 trial for reduction of pain, inflammation

InSite Vision completes enrollment in BromSite Phase 3 trial for reduction of pain, inflammation

Enrollment complete in DOUBle Phase 3 clinical trial of AzaSite Plus and DexaSite for blepharitis

Enrollment complete in DOUBle Phase 3 clinical trial of AzaSite Plus and DexaSite for blepharitis

DuraSite 2 ophthalmic drug delivery system from InSite Vision

DuraSite 2 ophthalmic drug delivery system from InSite Vision

InSite Vision second quarter total revenues decrease to $1.8 million

InSite Vision second quarter total revenues decrease to $1.8 million

InSite Vision commences enrollment in BromSite Phase 3 clinical trial

InSite Vision commences enrollment in BromSite Phase 3 clinical trial

InSite Vision first quarter total revenues decrease to $2.3 million

InSite Vision first quarter total revenues decrease to $2.3 million

UCSF appeals USPTO panel judgment in favor of InSite Vision

UCSF appeals USPTO panel judgment in favor of InSite Vision

Insite Vision announces completion of patient enrollment in ISV-303 Phase 1/2 trial for post surgical ocular pain, inflammation

Insite Vision announces completion of patient enrollment in ISV-303 Phase 1/2 trial for post surgical ocular pain, inflammation

InSite Vision initiates Phase 1/2 clinical trial of ISV-303

InSite Vision initiates Phase 1/2 clinical trial of ISV-303

InSite Vision to advance new development candidate ISV-303

InSite Vision to advance new development candidate ISV-303

AzaSite production increased to combat erythromycin ophthalmic ointment shortage

AzaSite production increased to combat erythromycin ophthalmic ointment shortage

FDA approves Besivance as a treatment for bacterial conjunctivitis

FDA approves Besivance as a treatment for bacterial conjunctivitis

FDA approves Besivance for the treatment of bacterial conjunctivitis

FDA approves Besivance for the treatment of bacterial conjunctivitis